Arcus Biosciences, Inc.RCUSNYSE

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was th.

seekingalpha.com

Arcus Biosciences: Q4 Beat And Casdatifan's Story So Far

Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS's valuation premium is driven by Casdatifan, a next-generation HIF-2α inhibitor showing superior efficacy and safety versus competitors in ccRCC. The company's $1.01B cash position funds operations into at least 2H28, supporting multiple Phase 3 programs and mitigating near-term financing risk.

seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript

businesswire.com

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, today reported financial results for the year and quarter ended December 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “This week's updated data at ASCO GU continue to va.

businesswire.com

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a post.

businesswire.com

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter and year ended De.

zacks.com

Rapid Innovation is Reshaping Oncology: Stocks in Focus

Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.

zacks.com

Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Arcus Biosciences (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 16,650 shares of the Company's common stock at an exercise price per share of $22.13, which was.

seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

businesswire.com

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today outlined its 2026 priorities for casdatifan and its emerging inflammation and immunology (I&I) programs. “As we enter 2026, the highest priorities for Arcus will be the rapid enrollment of PEAK-1, our Phase 3 study evaluating casdatifan in immunotherapy.

fool.com

Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return

82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, leaving the insider with 367,220 direct shares and 954,063 shares held via trust.

defenseworld.net

Robert Goeltz II Sells 6,552 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE: RCUS - Get Free Report) CFO Robert Goeltz II sold 6,552 shares of the firm's stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $23.38, for a total transaction of $153,185.76. Following the sale, the chief financial officer owned 67,924 shares in the company,

businesswire.com

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14th, 2026, at 3:00 pm PT. A live.

seekingalpha.com

Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221

RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they'll focus now on Casdatifan (AB521), which is a wholly owned oral HIF-2α inhibitor. In my view, this makes Casdatifan the core bull thesis, especially with the Phase 3 PEAK-1 results going forward.

zacks.com

RCUS Stock Down on Decision to Discontinue GILD Partnered Study

Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.

benzinga.com

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility.

investors.com

Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.

businesswire.com

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc., due to futility. The decision is based on the recommendation from the Independent Data Monitoring Committee (IDMC).

businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 3,600 shares of the Company's common stock at an exercise price per share of $25.80, which was the clo.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance